Short answer
Vaxcyte, Inc. (PCVX) filed an 8-K current report with the SEC on July 15, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers). Heath Lukatch retiring from Vaxcyte’s Board effective July 16, 2026 after more than eight years.
Vaxcyte, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- Heath Lukatch retiring from Vaxcyte’s Board effective July 16, 2026 after more than eight years
- Retirement unrelated to disagreement or dispute, reducing governance concern
- John Markels appointed Class II director through 2028 annual meeting
- Markels joins Audit and Compensation Committees as a Nasdaq-independent director
- Annual equity grant value currently $430,000 under the non-employee director compensation program
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Vaxcyte, Inc. 8-K filings
Get the next PCVX 8-K as it lands
Follow PCVX for push alerts, or ask the research agent what this filing means.